Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Colorectal Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × NIS-793 × Clear all
NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Terminated
4 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04952753 2025-03-26

daNIS-3

Novartis

Phase 2 Terminated
204 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05546411 2024-12-17

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡